Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Hepatol. Feb 27, 2018; 10(2): 308-318
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.308
Figure 1
Figure 1 Overall survival of patients with preoperative AFP < 10 ng/mL, ≥ 10 to < 400 ng/mL, and ≥ 400 ng/mL. AFP: Alpha-fetoprotein. bP < 0.01.
Figure 2
Figure 2 Disease-free survival of patients with preoperative AFP < 10 ng/mL, ≥ 10 to < 400 ng/mL, and ≥ 400 ng/mL. AFP: Alpha-fetoprotein. bP < 0.01.
Figure 3
Figure 3 Receiver operating characteristic curve for alpha-fetoprotein in predicting hepatocellular carcinoma recurrence after liver transplant.
Figure 4
Figure 4 Overall survival of patients with preoperative alpha-fetoprotein ≤ 105 ng/mL and > 105 ng/mL. AFP: Alpha-fetoprotein. bP < 0.01.
Figure 5
Figure 5 Disease-free survival of patients with preoperative alpha-fetoprotein ≤ 105 ng/mL and > 105 ng/mL. AFP: Alpha-fetoprotein. bP < 0.01.